

DROPERIDOL (Inapsine) EMSAC JULY 2025

ACTION: Butyrophenone

- Droperidol produces a dopaminergic blockage, a mild alpha-adrenergic blockage, and causes peripheral vasodilation
- Onset of Action: 3 to 10 minutes after IM administration
- Duration: 2-3 hours

INDICATIONS: First line medication for severely agitated patients who pose serious probable and imminent bodily harm to self/others

CONTRAINDICATIONS:

- Suspected acute myocardial infarction/acute coronary syndrome
- Hypotension (systolic blood pressure under 100mmHg, or the absence of a palpable radial pulse)
- Pregnancy
- Dementia related psychosis
- Patients < 18 years

POTENTIAL SIDE EFFECTS

- Transient hypotension
- Dystonic reaction
- Extra-pyramidal reactions
- Sedation

ADULT DOSE:

5mg Intramuscular X 1

PEDIATRIC DOSE:

N/A

NOTES:

- Caution use in patients >60 years of age
- May cause prolonged QT interval. Caution in patients with known prolonged QT syndrome or recent simultaneous use of other QT-prolonging drugs.
- All patients receiving droperidol should be placed on cardiac monitoring and EtCO2 monitoring. Although obtaining an ECG on the combative or agitated patient may be difficult, an should be made to do so.
- Avoid patients known to be pregnant, regardless of gestational age
- Contact Base Hospital if additional doses of droperidol or midazolam are needed for patients with continued agitation after first dose of triperidol.